id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-P-0007-0022,FDA,FDA-2006-P-0007,See Document ID FDA-2008-D-0626-0002 re Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl Notice of Availability  Reference,Supporting & Related Material,REF-Reference Material (external attachments),2008-12-24T05:00:00Z,2008,12,,,2014-02-01T00:56:34Z,,0,0,09000064807f2141
FDA-2006-P-0007-0019,FDA,FDA-2006-P-0007,FDA/ViroPharma - Minutes of Meeting,Other,MM-Memorandum of Meeting,2008-12-11T05:00:00Z,2008,12,2008-12-11T05:00:00Z,,2008-12-21T03:21:44Z,,0,0,09000064807d7b1e
FDA-2006-P-0007-0021,FDA,FDA-2006-P-0007,ViroPharma Slide Presentation Vancocin Bioequivalence (BE) Appropriate Method Development FDA Meeting January 7 2008  re FDA-2006-P-0007-0020,Supporting & Related Material,C-Comment (Supporting and Related Material),2008-12-11T05:00:00Z,2008,12,,,2014-02-01T00:54:04Z,,0,0,09000064807d7d80
FDA-2006-P-0007-0020,FDA,FDA-2006-P-0007,ViroPharma Incorporated - Letter,Other,LET-Letter,2008-12-11T05:00:00Z,2008,12,2008-12-11T05:00:00Z,,2010-11-03T16:48:34Z,,0,0,09000064807d7d09
FDA-2006-P-0007-0018,FDA,FDA-2006-P-0007,ViroPharma Incorporated - Supplement Petition,Other,SUP-Supplement,2008-12-11T05:00:00Z,2008,12,2008-12-11T05:00:00Z,,2013-07-27T22:19:34Z,,0,0,090000648069607b
FDA-2006-P-0007-0016,FDA,FDA-2006-P-0007,ViroPharma - Supplement,Other,SUP-Supplement,2008-06-23T04:00:00Z,2008,6,2008-06-23T04:00:00Z,,2008-06-24T00:30:39Z,,0,0,090000648062bae0
FDA-2006-P-0007-0014,FDA,FDA-2006-P-0007,"Congressional Record - Senate (S5649-5650), May 7, 2007 - [D. Robertson - Comment]",Supporting & Related Material,EMC-E-Mail  (Supporting and Related Material),2008-04-16T04:00:00Z,2008,4,,,2009-02-10T17:36:41Z,,0,0,0900006480441490
FDA-2006-P-0007-0006,FDA,FDA-2006-P-0007,ViroPharm Incorporated - Letter,Other,LET-Letter,2008-04-16T04:00:00Z,2008,4,2008-04-16T04:00:00Z,,2008-04-16T23:22:23Z,,0,0,0900006480441455
FDA-2006-P-0007-0003,FDA,FDA-2006-P-0007,Petition for stay from ViroPharma Incorporated,Other,PSA-Petition for Stay,2008-04-16T04:00:00Z,2008,4,2008-04-16T04:00:00Z,,2019-07-08T14:48:05Z,,0,0,0900006480441450
FDA-2006-P-0007-0007,FDA,FDA-2006-P-0007,"ViroPharma, Inc. - SUP  - Supplement",Other,SUP-Supplement,2008-04-16T04:00:00Z,2008,4,2008-04-16T04:00:00Z,,2019-07-08T14:48:59Z,,0,0,090000648044146d
FDA-2006-P-0007-0015,FDA,FDA-2006-P-0007,See FDA-2006-P-0007-0014,Supporting & Related Material,EMC-E-Mail  (Supporting and Related Material),2008-04-16T04:00:00Z,2008,4,,,2009-02-10T17:37:31Z,,0,0,0900006480441498
FDA-2006-P-0007-0004,FDA,FDA-2006-P-0007,"Petition for Stay from ViroPharma Incorporated March 30, 2006",Other,PSA-Petition for Stay,2008-04-16T04:00:00Z,2008,4,2008-04-16T04:00:00Z,,2019-07-08T14:48:34Z,,0,0,0900006480441452
FDA-2006-P-0007-0005,FDA,FDA-2006-P-0007,Acknowledgement Letter to ViroPharma Incorporated,Other,ACK-Acknowledgement Letter,2008-04-16T04:00:00Z,2008,4,2008-04-16T04:00:00Z,,2008-06-24T00:32:45Z,,0,0,0900006480441454